Anemia is a common complication of chronic renal failure patients, the prevalence increases with decreased renal function. This is reported in patients with normochromic, normocytic anemia. However, the reasons are multifactorial, the main factor comorbidity rate of iron deficiency and erythropoietin deficiency. End-stage renal disease (ESRD) from the process stage of anemia in ESRD has been increasing and is growing in depth. This article aim anemia epo treatment of patients diagnosed with ESRD and evaluate the situation, the relationship between the frequency of anti-hypertensive drug use manifest. Treated in our dialysis center and included in this study, the monthly average of all 73 patients, three sessions per week and admitted that at least four hours each session, is composed of adult individuals. The study, between January 2009 and October 2009 including 10 months retrospectively periyotu capable. Possible blood loss during treatment in our unit have undergone special training for all staff. Blood samples of Fe - epo treatment practices at the earliest, after 3 weeks and was taken as prehemodiyaliz. According to the results of hemoglobin and the use of antihypertensive medication patients, divided into three groups. Epo applications in our unit, except for a few exceptions, patients were subcutan. Study on the preparations, epoetin alfa, epoetin beta 50-150 iu / kg / wk rHuEPO and darbepooetin alpha half-life of the people once a week for as long 0.25-0.75 g / kg administered in the form. The results were as follows: anti-hypertensive drug utilization rates in the treatment of anemia in patients with blind, being treated for anemia (Hb <12g/dl) anti-hypertensive drug utilization rates in patients with serious difference between the month of March were excluded. In March, the approximately equal values increased. Epo-treated patients (Hb <11g/dl) 10-month basis, while 37% of the total incidence of HT, epo therapy in patients with blind 10-month prevalence of 21% of HT have been identified as the base. No statistically significant difference between these two values are (P = 0.001 <0.05). Epo treatment with anti-hypertensive drug use booster contribution rate, to work with once again been put forward. Get out of Epo in the treatment of this effect is seen most preparate epoetin beta, although the increase in HT was thought by other pathogens was considered that this difference is not significant.